[nomadking]

Originally Posted by 1andrew1

This is the announcement of the AstraZeneca deal with Europe:
https://www.astrazeneca.com/media-ce...no-profit.html

Here is the redacted Curevac contract which is in the public domain. Probably the closest we can get to at this stage as to what the AstraZeneca one will have looked like.
https://ec.europa.eu/info/sites/info...greement_0.pdf

Technically the agreement wasn't with the EU, but with certain EU countries. It was before the EU wide arrangement.
Elements of the EU supply chain were already in place, so can't have been EU funded.

With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly.

Cobra Biologics has been producing pharaceuticals for more than 20 years. It has two facilities on Keele University’s Science and Innovation Park making the vaccine in a partnership with the global pharmaceutical giant.

That site has been there for more than 20 years, so the EU cannot claim "ownership".
Other sites involved also were built before Covid surfaced.

Oxbox was originally built to solely service the Group’s growing demand for lentiviral vectors in the fast growing cell and gene therapy market where it is a leading global specialist working with multiple partners including Novartis, BMS and Sanofi. The Oxbox facility was completed at the end of 2019 with the Group expecting to have one or potentially two of the manufacturing suites approved during 2020. In April 2020 the Group joined the Oxford Vaccine Consortium and shortly afterwards signed the first of two agreements with AstraZeneca for COVID-19 vaccine production. By October 2020, the Group had four manufacturing suites approved by the MHRA, three of which were contracted by AstraZeneca and are currently producing bulk vaccine at 1000L scale.

Ian McCubbin, the manufacturing lead for the UK's Vaccine Taskforce said that the “vast majority” of the Oxford/AstraZeneca vaccine will be manufactured in the UK.
AstraZeneca also has some plants in Europe, with sites in Germany and the Netherlands producing the jab - these were the first to be rolled out in the UK.

The Belgian plant that was raided was opened in 2018, so again the EU cannot claim "ownership".


The Curevac agreement defines "reasonable best efforts" and that one factor is "yield of product". It also refers to "estimated delivery schedule", implying delivery dates are not to be set in stone.